Weekly bisphosphonates line up head-to-head.

Australian Doctor,  February, 2007  

• E-mail
• Print
• Link

By Cathy Saunders

ONCE-weekly risedronate and alendronate both reduce osteoporotic fractures in postmenopausal women but risedronate provides significantly greater protection, research suggests.

The head-to-head study of bisphosphonates risedronate (Actonel) and alendronate (Fosamax) included more than 33,000 women aged 65 and over and showed patients newly prescribed risedronate were more than 40% less likely to have a hip fracture at six and 12 months than those taking alendronate.

Patients on risedronate were also about 18% less likely to have non-vertebral (hip, wrist, ...

Read the rest of this article with a Free Trial at HighBeam Research.